Chinese Experts Consensus on Immune Checkpoint Inhibitors 
for Non-small Cell Lung Cancer (2020 Version)

Chinese Experts Consensus on Immune Checkpoint Inhibitors 
for Non-small Cell Lung Cancer (2020 Version)

Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer. The systemic antitumor therapy of advanced NSCLC has undergone renovations of chemotherapy, targeted therapy and immunotherapy, which results in greatly improved survival for patients with advanced NSCLC. Immune...

Full description

Bibliographic Details
Main Authors: Caicun ZHOU, Jie WANG, Baocheng WANG, Ying CHENG, Zhehai WANG, Baohui HAN, You LU, Gang WU, Li ZHANG, Yong SONG, Bo ZHU, Yi HU, Ziping WANG, Qibin SONG, Shengxiang REN, Yayi HE, Xiaohua HU, Jian ZHANG, Yu YAO, Hongyun ZHAO, Zhijie WANG, Qian CHU, Jianchun DUAN, Jingjing LIU, Shukui QIN
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2021-04-01
Series:Chinese Journal of Lung Cancer
Subjects:
lung neoplasms
immunotherapy
programmed cell death protein 1/programmed death-ligand 1
expert consensus
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.13

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.13

Similar Items